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Abstract 
Tardive dyskinesia (TD) is a movement disorder that is a common side effect of antipsychotic 
medications used in the treatment of mental illness. The case presented in this paper is from a 
patient in their sixties with a long history of treatment for their mental illnesses and substance 
abuse. During the course of treatment, this patient developed severe TD. The literature review 
focused on past, current and new treatments for TD and in addition, the hypothesized causes for 
tardive dyskinesia. New treatments and their effectiveness may give a Psychiatric Nurse 
Practitioner better understanding of the cause of TD and how to treat it once it is recognized or 
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Background 
 Tardive dyskinesia (TD) is described in the Diagnostic and Statistical Manual of Mental 
disorders (5th ed.) (American Psychiatric Association, 2015) as choreiform or athetoid 
involuntary movements that occur in the face, mouth, extremities, trunk, diaphragm and 
pharyngeal areas. Movements must last at a minimum of a few weeks and be associated with the 
use of neuroleptic medication for a few months. Older people may develop symptoms of TD in a 
shorter period and in some persons, symptoms may present following changes, reductions or 
discontinuation of their neuroleptic medications. If symptoms occur following a change, 
reduction or discontinuation they are classified as neuroleptic withdrawal-emergent dyskinesia 
and typically resolve in 4-8 weeks. Movements that meet criteria for TD that persist beyond this 
time period are diagnosed as TD (American Psychiatric Association, 2013).  
 TD has the potential to be a permanent hyperkinetic involuntary movement syndrome 
associated with the use of dopamine receptor-blocking agents (DRBAs), classes of medications 
that have this mechanism of action include antipsychotics, antiemetics, tricyclics, medications 
for gastrointestinal disorders and others. Several management strategies are recognized for TD, 
none were established or standard FDA-approved until recently (Khouzam, 2015).  
 Until 2017, TD management consisted mainly of off-label use of medications, switching 
to another agent, medication discontinuation and supplements. Last year the FDA approved the 
first medication treatment for TD in adults (Uhlyar & Rey, 2018). This new treatment not only 
gives hope to individuals that suffer from TD but could also have the added benefit of reducing 
current medication regimens and the associated side effects.  
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Case Report 
 The client in my case report (in their 60’s now) is being managed for her mental health 
and substance abuse disorders in an outpatient setting and was seen for routine psychiatric 
assessment and medication management follow up. Most recent mental health history includes 
Alcohol Use Disorder (Severe), Alcohol Induced Dementia and Borderline Personality Disorder. 
Client was recently admitted to the long-term psychiatric hospital after a relapse on alcohol, 
treated for less than a week and discharged to the community. Other psychiatric diagnoses 
include: Schizoaffective disorder (Bipolar type), Unspecified Anxiety Disorder and TD. 
Currently she is prescribed Trazodone at night as needed for sleep and Ingrezza for the TD.  
 This client has a long and extensive mental health history dating back to childhood. The 
client endorsed hyperactivity in childhood that lead to frequently being in trouble in the 
classroom due to not being able to sit still. Later in life this was discussed as symptoms either 
due to anxiety or ADHD. Drug and alcohol use began around the age of 16 and the client was 
treated for addiction at the age of 17. During the first inpatient treatment for substance abuse the 
first psychiatric hospitalization occurred. The client was not able to recall the circumstances 
leading up to the first inpatient psychiatric treatment. Historical data accuracy is unknown due to 
the diagnosis of alcohol induced dementia. Endorsed symptoms of her illness in the past include; 
multiple suicide attempts, auditory hallucinations (AH) and anxiety.  
 This client has had more than thirty inpatient treatments for both mental health and 
substance abuse going back 40 years. Prior psychiatric psychotropic medication treatment 
include benztropine for extrapyramidal symptoms, trazodone for sleep, bupropion for mood, 
quetiapine for AH, venlafaxine for mood, olanzapine for AH, hydroxyzine and clonazepam for 
anxiety, aripiprazole, risperidone and ziprasidone for AH, paroxetine and Depakote for mood, 
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fluphenazine, trifluoperazine and  Thorazine for AH and Remeron for sleep. The prior 
medication list could be more extensive as I only had record access going back to 2015.   
 At the most recent follow up appointment the client denies any mood or psychotic 
symptoms, and reports using her Trazodone for sleep a couple times a week. This client was 
prescribed Ingrezza three months ago and has been taking it daily at 80 mg for about 2.5 months. 
Prior to the Ingrezza this client showed symptoms of severe TD including movements of the 
mouth, tongue and extremities per previous antipsychotic involuntary movement scales (AIMS) 
assessments going back to 2015. At the most recent appointment the client was scored a zero on 
AIMS with only minimal quivering of her mouth/lips that did not meet criteria for facial/oral 
movements. This was a significant change from scoring 4’s (severe) in these areas in past AIMS 
assessments. The client’s most recent relapse on alcohol is being treated with Vivitrol and 
therapy was recommended, substance abuse is where the individual struggles currently, after, per 
the client being able to abstain from use for a period of time, that was lengthy for her. No 
medication changes were made at her most recent psychiatric visits for medication follow up, 
and the client was pleased with the positive effect the Ingrezza had on the TD. She denied any 
adverse side effects of the medication. 
 This was the first case of TD treated with Ingrezza at the long-term psychiatric facility 
after only learning of the new treatment in recent months. A prior authorization (PA) was needed 
to get this medication approved by the client’s insurance. Per the prescribing provider the 
company that produces Ingrezza made the process simple with paperwork specific for this 
medication available to fill out and submit to a client’s insurance company. The approval was 
processed within the same week as the PA was sent to the insurance company. Positive results 
like this warrant a change in how TD is treated for any provider with clients that show symptoms 
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of this movement disorder. Further research based on a case study example as this, should be 
shared with other psychiatric providers to improve prescribing practices for neuroleptic 
medications.  
Literature Review 
History of Tardive Dyskinesia 
 My literature search included the data bases: PubMed, CINAHL Complete and 
PsychINFO using the terms “tardive dyskinesia”, “tardive dyskinesia treatment”, “tardive 
dyskinesia case studies”, “tardive dyskinesia differential diagnosis” and “tardive dyskinesia in 
patients treated with atypical antipsychotics”. Ten results were found and used that fit the criteria 
for this independent study. Other sources of information included the DSM-V, American 
Academy of Neurology and the National Institute of Health. 
 Antipsychotic medications (neuroleptics) were first used in the 1950’s. Their use caused 
a great change in the treatment of psychotic disorders. The first published report of orofacial 
involuntary movement that was irreversible was in 1957. This case involved treatment with the 
medication megaphen, a derivative of the antipsychotic phenothiazine. TD became an official 
term in 1964 to represent the delay in onset of symptoms of TD between antipsychotic use and 
abnormal movements (Khouzam, 2015). As of 1972 all antipsychotic medications began to carry 
the warning of TD with the packaging. The formal international definition of TD includes the 
classic signs of face-cheek-tongue movements referred to as the buccolingual masticatory 
syndrome. Movements include lip smacking, tongue thrusting or protruding, side to side jaw 
movements and sucking behaviors. TD movements can become more pronounced during times 
of stress or while moving another part of the body such as walking. The movements do not occur 
at all during sleep. Other uncontrolled movements of TD include choreiform of the feet and 
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hands, dystonia of the trunk and neck, asynchrony of the diaphragm effecting breathing and 
athetosis of the extremities (Khouzam, 2015). 
  The 1990’s brought about new medications for the treatment of psychotic disorders 
known as second-generation antipsychotics (SGAs). There was hope this new class of 
medications would be an effective treatment for psychosis while carrying a lower risk for side 
effects such as TD. Unfortunately, this hope has diminished due to reports of this medication 
class’s potential for causing TD along with increased risk of cerebrovascular and cardiovascular 
morbidity and mortality. The risk of TD is greater in the elderly population, lower doses of both 
first generation antipsychotics (FGAs) and SGA’s should be used, and the risk/benefit analysis 
must be done cautiously.  
Pathophysiology of TD 
 The pathophysiology of TD is yet to be definitively understood. The leading hypothesis is 
that TD is the result of chronic dopamine receptor blockage. In particular, this includes the 
dopamine receptors D2 and D3 by DRBAs. This hypothesis helps explain one of the other 
leading theories of TD. The theory says that TD is the result of long-term exposure to 
neuroleptics, D2 receptors upregulation and receptors becoming over sensitive at postsynaptic 
neuronal dopamine sites. This theory fails to explain why TD can be life-long in individuals that 
stop taking DRBAs as the idea would be that dopamine receptor super sensitivity would lessen 
as the receptors down regulate (Waln & Jankovic, 2013).  
 Another hypothesis of TD that has been supported in animal studies involving primates 
and rodents speculates that damaged or dysfunctional striatal y-aminobutyric acid (GABA) 
neurons can result in GABAergic low function and degeneration of the striatal fast-spiking 
interneurons that control the balance of indirect and direct basal ganglia pathways. This theory 
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named the “maladaptive synaptic plasticity” hypothesis believes that both D2 increased 
sensitivity and degeneration of neurons due to increased oxidative stress leads to negative effects 
on synaptic plasticity of glutaminergic synapses at the striatum. These changes create an 
imbalance of both direct and indirect basal ganglia pathways leading to abnormal messaging to 
the sensorimotor cortex. This abnormal information could result in improperly coded motor 
programming and abnormal movements (Waln & Jankovic, 2013).  
 The “neurodegenerative hypothesis” is a theory that helps explain the chronicity of TD in 
some individuals. This theory suggests that neuroleptic medications can increase free radical 
formation through increased lipid peroxidation. This can lead to damaged neurons and 
degeneration of various neurotransmitter systems. Chronic neuroleptic use is associated with an 
increase in free radical production and an impaired antioxidant system. Changes in some 
enzymes such as manganese superoxide dismutase and the superoxide dismutase gene are also 
related to TD (Waln & Jankovic, 2013).  
 At an individual level genetic susceptibility may help explain why some people taking 
neuroleptics develop TD while the majority do not. Many gene candidates are proposed to have 
an effect on a person’s predisposition for developing TD. Dopamine, serotonin, manganese 
superoxide dismutase, Catechol-O-methyltranferase COMT and others are theorized to possibly 
increase the risk of TD (Waln & Jankovic, 2013).  
Epidemiology of TD 
 Reporting on TD in patients goes back as far as the 1950s, very soon after the first 
antipsychotic medications were being used in psychiatry practice. Although met with skepticism 
during the first few years of studying medications and patient behavior, several patient 
experiences worldwide have confirmed the relationship between antipsychotic drugs (APD) and 
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TD. Initial study results showed a risk of developing TD of 32% for patients taking APDs for 5 
years, at 15 years there was a 57% risk of developing TD and after 25 years 68% risk of 
developing TD (D’Abreu, Akbar & Friedman, 2018). Later study results varied greatly with 
some studies showing far less incidences of TD with the SGAs while other studies showed no 
significant differences between FGAs and SGAs incidence of TD. A recent meta-analysis 
(D’Abreu, Akbar & Friedman, 2018) of over 40 studies between 2000 and 2015 that compared 
TD incidence between FGAs and SGAs showed a mean prevalence of 25.3% for all participant 
treatment groups. Population prevalence varied greatly from 8% in some populations to 75% in 
others. Population variations included: APD class, length of treatment with APD’s, duration of 
illness, geographical region and baseline parkinsonism.  
 One cross-sectional study by D’Abreu, Akbar & Friedman (2018) of patients taking 
APD’s found the TD prevalence to be about 33% of the 180 patients studied. This study also 
identified the most common causing antipsychotic medication. Perphanazine was the highest at 
34.4% of a prevalence risk of developing TD, fluphenazine 16.6%, thioridazine 15.6%, 
chlorpromazine 11.1%, trifluperazine 8.3%, fluphenazine 6.7% (oral form), thiothixene 5.3% 
and haloperidol at 5.0% (D’Abreu, Akbar & Friedman, 2018).  
Risk Factors 
 Several risk factors have been identified that can increase the chances of developing TD. 
The risk factors that increase the risk of TD include the total dose of the antidopaminergic 
agent/s over a lifetime, especially high doses of FGAs, adjunctive treatment with lithium, having 
a history of extrapyramidal symptoms (EPS), tobacco use, alcohol use, psychostimulant use, and 
history of central nervous system (CNS) damage (Szafranski, 2014). Additional risk factors 
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found in a study by Cornet et al. (2017) include being female, old age, being African or African 
American.  
Other Causative Agents of TD 
 It has been well established in several studies (Cornett et al., 2017) that there is a cause 
and effect relationship between both FGAs/SGAs and TD. Several other classes of medications 
have been found to either cause TD or make it worse. Antiemetics will often potentiate the risk 
of a client developing TD due to dopamine antagonism. Metoclopramide has a strong association 
with developing TD. Anticholinergics such as procyclidine which is used for chronic obstructive 
pulmonary disease (COPD), bladder control and to treat EPS and Parkinson disease symptoms 
has been shown to increase TD. Other classes of medications that have shown an increased risk 
for developing TD include antidepressants (AD), anticonvulsants, antihistamines, decongestants, 
antimalarials, anxiolytics, biogenic amines, mood stabilizers and stimulants (Cornett et al., 
2017). 
Assessments for TD 
 Two commonly used assessments for TD include the AIMS and the Dyskinesia 
Identification System: Condensed User Scale (DISCUS). It is recommended that clinicians 
prescribing known TD causing medications to perform an assessment for TD at initiation of the 
medication and at least annually thereafter. Six-month assessments are recommended in the 
elderly population. The AIMS was created in the 1970’s for the purpose of monitoring the 
development of TD. This assessment can be performed by any trained health care professional. 
The assessment takes about 10 minutes and measures 12 different items that are rated 0 (none) to 
4 (severe). The results are generally not communicated to the client and a score of 2 or higher 
indicates TD. If the diagnosis of TD is suspected based on the AIMS score interventions include 
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assessing whether the client needs to be on the causing agent, dose reduction and a trial of 
clozapine as an alternative treatment. Clozapine use has shown little to no risk of developing TD 
and clients trialed or switched to this medication have experienced improvements in their TD 
(National Institute of Mental Health, n.d.). Another assessment tool is the DISCUS which is done 
at baseline, annually or every six months and monthly for 3 months following causative agent 
discontinuation. Criteria for use include cumulative three-month exposure to an APD and a score 
of 5 or above indicates TD (University of South Florida, n.d.). The DISCUS is a a more in-depth 
assessment, although the AIMS is more commonly used in clinical practice. Table 1 is the form 
used to perform an AIMS assessment. (see Appendix for the form used to perform an AIMS 
assessment) 
Treatments for TD 
 According to an article by Citrome (2018), a five-step management strategy that can be 
used in the assessment and treatment of TD. Step 1 is recognition. Providers that prescribe APDs 
should recognize the high possibility of the development TD in clients. Although this risk can be 
mitigated with the use of SGAs there is still a prevalence rate of developing TD at around 20%. 
With the increasing use of APDs for other mental illnesses such as augmentation for major 
depressive disorder (MDD), the risk of developing TD is on the rise. Step 2 is effective 
assessment. Trained observation is required to assess for the symptoms of TD. Using a 
standardized rating scale such as the AIMS is useful for tracking risk of a client developing TD 
over time. Step 3 is harm reduction by decreasing the risk of TD. The ideal intervention would 
be to prevent TD, but this is not possible for all patients in all situations. With providers working 
in psychiatry being experts in the risk factors related to psychotropic medications, higher 
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causative agents and finding alternative treatments to DRBAs can help reduce the risk of clients 
developing TD. Step 4 is the intervention phase. When TD has been recognized in a client, steps 
are taken to address the TD. Recognized options for addressing TD include stopping/reducing 
the DRBA, switching from an FGA to an SGA and discontinuing any anticholinergic types of 
medications. Step 5 relates to following up with current symptoms and treatment plan 
effectiveness. The AIMS assessment is a useful tool for assessing progression of TD symptoms 
and should be done at treatment initiation and recommended intervals. AIMS assessment by 
itself is not enough to assess the effect of TD on a client. Further assessment questioning 
regarding impairments in functioning in various life areas should also be pursued during regular 
assessment intervals (Citrome, 2018).  
 Other testing that can be done to rule out other causes for involuntary movements include 
laboratory studies such as serum ceruloplasmin and the copper transporter gene of Wilson’s 
disease. Imaging studies can also be helpful as they are typically normal in a client with TD. 
Imaging studies can assist in the differential diagnosis related to involuntary movements such as 
Huntington disease (Khouzam, 2015).  
 Additional treatment options for TD that have been and are being used off label include 
clonazepam, for which some benefit has been shown in TD (Citrome, 2018). The side effects and 
abuse potential must be weighed when considering prescribing benzodiazepines. Gingko biloba 
is thought to help due to its antioxidant properties. Anticholinergics have been used to treat EPS 
but really show no benefit in the treatment of TD. Anticholinergics have been shown in some 
cases to aggravate symptoms of TD. There is minimal evidence for the use of botulinum toxin 
intramuscular (IM) injections in the treatment of TD. Tetrabenazine was commonly used to treat 
TD due to its effectiveness in the treatment of Huntington’s chorea. Data concluded that 
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Tetrabenazine is lacking in effectiveness for treatment of TD. There is also a significant side 
effect profile of this medication making it a poor choice for the treatment of TD. Other 
medications that have been used off label but lack any evidence for effectiveness in the treatment 
of TD include levetiracetam, propranolol and zolpidem.  
 New treatments “approved” for TD.  
 As of 2017 the FDA has approved two new medications for the treatment of TD in adults. 
The first was Ingrezza (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor. 
The action of this medication allows less new and recycled dopamine to be transported into 
vesicles in the presynaptic neuron, thus less dopamine is available to be transported into the 
synapse during neurotransmission. This reduction in dopamine in the synapse is thought to help 
with the upregulation and over sensitization of postsynaptic dopamine receptors. The mechanism 
of action and effectiveness is proof that the theory behind the pathophysiology of TD involves 
chronic dopamine receptor blockage leading to upregulation and supersensitivity (Uhlyar & Rey, 
2018). As of the publication of this article by Uhlyar & Rey (2018) the efficacy and safety of 
valbenazine had been studied in two randomized, double-blind, placebo-controlled trials, Kinect 
2 and 3. Both trials used AIMS scores to rate the status of TD in the participants. Valbenazine 
differed from previous VMAT2 inhibitors by being effective without a significant side effect 
profile. In the Kinect 2 study at 6 weeks the reduction in AIMS scores for the experimental group 
was 3.6 while the control group was 1.1. The Kinect 3 trial at 6 weeks showed a mean reduction 
in AIMS scores of 3.2 vs. the placebo group.  
 Adverse effects based on combined data from both treatment groups showed the highest 
being somnolence and anticholinergic effects. Dosing recommendations for valbenazine is an 
oral dose of 40 mg daily for 1 week, then 80 mg daily. QT prolongation was identified as an 
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adverse effect with the use of valbenazine. A pre-treatment ECG is warranted prior to use with 
clients. No studies have been done in pediatric or geriatric populations and the FDA has not 
approved its use in these populations. Clients with hepatic/renal failure should continue to 
receive the 40 mg daily. There is little data in in study to support valbenazine’s use in pregnancy 
and female clients should be cautioned about the risks. Animal studies showed negative effects at 
birth and the metabolite of valbenazine was found in the milk of rodents. Valbenazine does have 
drug-drug interactions that warrant consideration such as monoamine oxidase inhibitors (MAOI), 
CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers along with digoxin (Uhlyar & Rey, 
2018). The price for valbenazine is high and there is no generic medication at this point. The 
manufacturer does provider a patient assistance program to help mitigate the cost for clients that 
can’t afford the medication. 
 The second medication to be approved for the treatment of TD in adults is Austedo 
(deutetrabenazine). Deutetrabenazine is another VMAT2 inhibitor. It was also studied in two 
trials, the ARM-TD and AIM-TD. Deutetrabenazine was initially approved for the treatment of 
Huntington’s chorea and later had its approval expanded by the FDA for TD in adults. Results 
were significant in both the treatment groups vs. placebo and like valbenazine, deutetrabenazine 
had a preferable side effect profile to previous VMAT2 treatments. Dosing for deutetrabenazine 
is 12 mg daily in divided doses and can be increased by 6mg daily to a max dose of 48 mg daily. 
Deutetrabenazine must be taken whole with food. There are drug-drug interactions with MAOI’s, 
reserpine and tetrabenazine, and caution should be taken in patients taking strong CYP2D6 
inhibitors. QT prolongation is a concern and an ECG should be considered prior to use along 
with caution for patients taking other medications known to cause QT prolongation. No 
medication changes are needed in patients with renal problems, and the medication is 
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contraindicated in hepatic impairment. Data in studies related to use in pregnant/breastfeeding 
women is lacking. Deutetrabenazine does have a black box waring for suicide and depression 
risk in Huntington disease patients along with several other warnings of side effects for this 
population (Touma & Scarff, 2018).  
 Comparing the two, seeing that both show similar efficacy in the treatment of TD in 
adults vs. placebo, valbenazine can be dosed once daily and does not require food, while 
deutatrabenazine is safer in patients with renal impairment. The black box warnings associated 
with deutetrabenazine are due to its approval for Huntington’s chorea patients. In the severe and 
persistently mentally ill population simplifying medication regimens is beneficial and once daily 
dosing would be a benefit for compliance. 
Case Study 
 In a case published by Kim, MacMaster & Schwartz (2014) a 67-year-old male client 
diagnosed with persistent depressive disorder was assessed to be lip wetting for about 1 year. His 
treatment for the previous 7 years included aripiprazole 10 mg daily and tiagabine at different 
doses between 4-24 mg daily. Anxiety was not fully controlled and buspirone 15 mg daily was 
prescribed. The client was maintained on this regimen for the next 4 years with good response. 
At his initial assessment in the new setting his lip wetting was thought to be due to chronic 
chapped lips and were controlled with over the counter (OTC) remedies. A different provider 
suspected TD as the cause for the behavior and tapered the client off the aripiprazole while 
leaving the other medications unchanged. The client’s mood remained stable for three months, 
but the lip wetting/smacking behavior continued. Tongue protrusions began to develop. The 
client’s TD symptoms became worse after discontinuation of the aripiprazole. Withdrawal TD 
was suspected, and several supplements were tried to relieve the symptoms pf TD. Supplements 
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including Vitamin E, Gingko biloba and branch chain amino acids were started without success 
and were stopped after shown to be ineffective in relieving TD symptoms. TD symptoms did 
improve over the next year but never completely resolved with discontinuation of aripiprazole. 
 This case study is a good example that SGAs can cause TD and discontinuation of the 
causing agent did help reduce the symptoms although not completely resolving them. At the time 
of this article the new VMAT2 medications were not available.  
Implications 
 Prior to the availability of the two new medications for treatment of TD, back in 2013 the 
American Academy of Neurology (AAN) (2013) released practice recommendations for the 
treatment of TD that a psychiatric nurse practitioner could utilize for managing care. Many 
medication agents were reviewed in the practice guideline that spanned several different classes 
of medications. The majority of medications reviewed for the treatment of TD were lacking in 
evidence for a therapeutic use in the treatment of TD (Peckham & Nicewonder, 2018). There 
will need to be more research to support the medications within the guidelines for the treatment 
of TD. 
 In the success of the case study client sample, a combination of both discontinuing the 
antipsychotic/s and anticholinergic medications, and the addition of valbenazine resolved the 
hyperkinetic movements of the client. Long term studies and practice-based data still needs to be 
gathered for both valbenazine and deutetrabenazine to determine side effects and long-term 
effects. Both medications are still undergoing post market investigation (Peckham & 
Nicewonder, 2018). Psychiatric nurse practitioners are in a unique role where education can be 
provided on the pros, cons, and risks of treatment. Participating in publishing case study 
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examples of treatment outcomes can assist with developing the evidence that is needed for long-
term studies of the side effects and benefits to clients.  
 Psychiatric nurse practitioners that prescribe medications that have the potential to cause 
TD need to first be aware that the medications they prescribe carry this adverse risk. Psychiatric 
nurse practitioners have a responsibility to stay current on the literature regarding the assessment 
for TD, causes of TD, and interventions and medications to treat TD. 
Conclusion 
 Although theories exist, the exact cause of TD is still a mystery. The connection between 
medication classes and TD has been established which gives psychiatric nurse practitioners best 
practice recommendations to follow when treating a psychotic disorder or augmenting with 
FGAs/SGAs for other mental illnesses. With the addition of new treatments for TD providers 
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Appendix 
Abnormal Involuntary Movement Scale (AIMS) 
Public Health Service      NAME: ________________________________________ 
Alcohol, Drug Abuse, and Mental Health Administration  DATE:  ______________________ 
National Institute of Mental Health     Prescribing Practitioner: _________________________ 
 CODE 0=None 
  1=Minimal, may be extreme normal 
INSTRUCTIONS:  2=Mild 
Complete Examination procedure (attachment d.)  3=Moderate 
Before making ratings  4-Severe 
MOVEMENT RATINGS:  Rate highest severity observed. Rate  RATER  RATER  RATER  RATER  
movements that occur upon activation one less than those observed      
spontaneously.  Circle movement as well as code number that applies. Date  Date  Date  Date  
     
Facial and  1. Muscles of Facial Expression  0 1 2 3 4  0 1 2 3 4  0 1 2 3 4  0 1 2 3 4  
Oral       e.g. movements of forehead, eyebrows, periorbital area,     
Movements       cheeks, including frowning, blinking, smiling, grimacing     
 2. Lips and Perioral Area  0 1 2 3 4  0 1 2 3 4  0 1 2 3 4  0 1 2 3 4  
     e.g., puckering, pouting, smacking      
3. Jaw e.g. biting, clenching, chewing, mouth opening, 0 1 2 3 4  0 1 2 3 4  0 1 2 3 4  0 1 2 3 4  
     lateral movement      
4. Tongue Rate only increases in movement both in and out  
    of mouth.  NOT inability to sustain movement.  Darting in 
    and out of mouth. 
0 1 2 3 4  0 1 2 3 4  0 1 2 3 4  O 1 2 3 4  
 5. Upper (arms, wrists,, hands, fingers)  
 Include choreic movements (i.e., rapid, objectively 
purposeless, irregular, spontaneous) athetoid movements 
(i.e., slow, irregular,    complex, serpentine).  DO NOT 
INCLUDE TREMOR  
(i.e., repetitive, regular, rhythmic)  
0 1 2 3 4  0 1 2 3 4  0 1 2 3 4  0 1 2 3 4  
Extremity 
Movements  
     
  
6. Lower (legs, knees, ankles, toes)  
e.g., lateral knee movement, foot tapping, heel dropping, 
foot squirming, inversion and eversion of foot.  
0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 
     
Trunk  
Movements 
7. Neck, shoulders, hips e.g., rocking, twisting, squirming, 
pelvic  gyrations 
 0 1 2 3 4  0 1 2 3 4  0 1 2 3 4  0 1 2 3 4  
Global  
8. Severity of abnormal movements overall  0 1 2 3 4  0 1 2 3 4  0 1 2 3 4  0 1 2 3 4  
9. Incapacitation due to abnormal movements 0 1 2 3 4  0 1 2 3 4  0 1 2 3 4  0 1 2 3 4  
Judgments           
10. Patient’s awareness of abnormal movements     
 Rate only patient’s report No awareness 0  
Aware, no distress 1 0  0  0  0 
 Aware, mild distress 2 1  1  1  1  
 Aware, moderate distress 3 2 2  2  2  
 Aware, severe distress 4            3            3             3          3 
   4  4  4  4  
Dental 
Status  
11. Current problems with teeth and/or dentures? 
No   Yes No   Yes No   Yes No   Yes 
12. Are dentures usually worn? No  Yes No   Yes No   Yes No   Yes 
     
 13. Edentia? No   Yes No   Yes No   Yes No   Yes 
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 14. Do movements disappear in sleep? No   Yes No   Yes No   Yes No   Yes 
National Institute of Health (n.d.) 
